PMID- 37816287 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231023 IS - 1618-095X (Electronic) IS - 0944-7113 (Linking) VI - 121 DP - 2023 Dec TI - Pharmacological mechanisms of sinomenine in anti-inflammatory immunity and osteoprotection in rheumatoid arthritis: A systematic review. PG - 155114 LID - S0944-7113(23)00474-9 [pii] LID - 10.1016/j.phymed.2023.155114 [doi] AB - BACKGROUND: Sinomenine (SIN) is the main pharmacologically active component of Sinomenii Caulis and protects against rheumatoid arthritis (RA). In recent years, many studies have been conducted to elucidate the pharmacological mechanisms of SIN in the treatment of RA. However, the molecular mechanism of SIN in RA has not been fully elucidated. PURPOSE: To summarize the pharmacological effects and molecular mechanisms of SIN in RA and clarify the most valuable regulatory mechanisms of SIN to provide clues and a basis for basic research and clinical applications. METHODS: We systematically searched SciFinder, Web of Science, PubMed, China National Knowledge Internet (CNKI), the Wanfang Databases, and the Chinese Scientific Journal Database (VIP). We organized our work based on the PRISMA statement and selected studies for review based on predefined selection criteria. OUTCOME: After screening, we identified 201 relevant studies, including 88 clinical trials and 113 in vivo and in vitro studies on molecular mechanisms. Among these studies, we selected key results for reporting and analysis. CONCLUSIONS: We found that most of the known pharmacological mechanisms of SIN are indirect effects on certain signaling pathways or proteins. SIN was manifested to reduce the release of inflammatory cytokines such as Tumor necrosis factor-alpha (TNF-alpha), Interleukin-6 (IL-6), and IL-1beta, thereby reducing the inflammatory response, and apparently blocking the destruction of bone and cartilage. The regulatory effects on inflammation and bone destruction make SIN a promising drug to treat RA. More notably, we believe that the modulation of alpha7nAChR and the regulation of methylation levels at specific GCG sites in the mPGES-1 promoter by SIN, and its mechanism of directly targeting GBP5, certainly enriches the possibilities and the underlying rationale for SIN in the treatment of inflammatory immune-related diseases. CI - Copyright (c) 2023 Elsevier GmbH. All rights reserved. FAU - Li, Juan-Min AU - Li JM AD - State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510006, China; International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. FAU - Yao, Yun-Da AU - Yao YD AD - State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Faculty of Chinese Medicine and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, China. FAU - Luo, Jin-Fang AU - Luo JF AD - Basic Medical College, Guizhou University of Traditional Chinese Medicine, Guian District, Guiyang, Guizhou, China. FAU - Liu, Jian-Xin AU - Liu JX AD - School of Pharmaceutical Sciences, Hunan University of Medicine, Huaihua, Hunan, China. FAU - Lu, Lin-Lin AU - Lu LL AD - International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. FAU - Liu, Zhong-Qiu AU - Liu ZQ AD - International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. FAU - Dong, Yan AU - Dong Y AD - Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510405, China. Electronic address: dondy001@gzucm.edu.cn. FAU - Xie, Ying AU - Xie Y AD - State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510006, China. Electronic address: leoxieying16@outlook.com. FAU - Zhou, Hua AU - Zhou H AD - State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510006, China; International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. Electronic address: gutcmzhs@hotmail.com. LA - eng PT - Journal Article PT - Review PT - Systematic Review DEP - 20230927 PL - Germany TA - Phytomedicine JT - Phytomedicine : international journal of phytotherapy and phytopharmacology JID - 9438794 RN - 63LT81K70N (sinomenine) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Morphinans) SB - IM MH - Humans MH - *Arthritis, Rheumatoid/drug therapy MH - Anti-Inflammatory Agents/pharmacology MH - *Morphinans/pharmacology/therapeutic use MH - Signal Transduction OTO - NOTNLM OT - Bone destruction OT - GBP5 OT - Inflammation OT - Rheumatoid arthritis OT - Sinomenine OT - mPGES-1 OT - alpha7nAChR COIS- Declaration of Competing Interest The authors declare no conflict of interest. EDAT- 2023/10/11 00:42 MHDA- 2023/10/23 01:18 CRDT- 2023/10/10 18:02 PHST- 2023/08/15 00:00 [received] PHST- 2023/09/05 00:00 [revised] PHST- 2023/09/20 00:00 [accepted] PHST- 2023/10/23 01:18 [medline] PHST- 2023/10/11 00:42 [pubmed] PHST- 2023/10/10 18:02 [entrez] AID - S0944-7113(23)00474-9 [pii] AID - 10.1016/j.phymed.2023.155114 [doi] PST - ppublish SO - Phytomedicine. 2023 Dec;121:155114. doi: 10.1016/j.phymed.2023.155114. Epub 2023 Sep 27.